-+ 0.00%
-+ 0.00%
-+ 0.00%
Teva olanzapine LAI TEV-749 faces FDA approval decision in Q4 2026
Share
Listen to the news
Teva olanzapine LAI TEV-749 faces FDA approval decision in Q4 2026
  • Teva’s investigational once-monthly subcutaneous olanzapine LAI TEV-749 faces an FDA PDUFA decision in Q4 2026.
  • European regulators accepted TEV-749’s marketing authorization application in May 2026, starting the EU review process.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609181630PRIMZONEFULLFEED1001263355) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending